Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one
Contents

Academy · Research Publication · GPP examples

Good Publication Practice Applied: Five Case Examples in Authorship, Disclosure and Data Sharing

Good Publication Practice (GPP) is most readily understood when applied to specific situations. This article examines five that commonly arise: an honorary author, an undeclared writer, an unfavourable trial result the sponsor may prefer not to publish, a congress abstract developed into a full paper, and an external request for data. In each case the guideline provides a usable answer.

Pubrica AcademyWritten by the medical writing and biostatistics teams Reviewed byPubrica biostatistics team Published9 October 2026 Last checked9 October 2026 Reading time13 minutes Sources31 peer-reviewed

The principles of Good Publication Practice (GPP) are not obscure, but principles alone do not indicate how to respond to a senior collaborator who expects authorship, or how to word an acknowledgement when a professional writer prepared the first draft. This article examines five situations, the requirements of the guideline in each and wording that satisfies them. Where published evidence addresses whether the recommended course is beneficial, it is reported, including where that evidence is weaker than commonly assumed.

Learning objectives

  • How to apply the ICMJE authorship criteria to a contested author
  • What a compliant writing-support disclosure contains, clause by clause
  • What GPP requires when a study’s results are unfavourable to the sponsor
  • How to handle data already presented at a congress without creating a duplicate publication
  • What a data sharing commitment must specify to be credible
  • What the published evidence does and does not show about declared writing support, including an odds ratio whose confidence interval nearly includes one

Common misconceptions

  • “Senior staff are always listed as authors; this is local practice.” The ICMJE criteria are cumulative, and a contributor who fails any one of them should be listed in the acknowledgements. Wislar and colleagues found inappropriate authorship still present in leading general medical journals, so local custom is not an accepted justification.
  • “If a writer drafted the paper, this cannot be disclosed.” The reverse is true. The American Medical Writers Association (AMWA), the European Medical Writers Association (EMWA) and the International Society for Medical Publication Professionals (ISMPP) all state that declared professional writing support is legitimate; concealment is not. Declaration is the remedy, not an admission.
  • “Declaring a medical writer improves the paper.” Gattrell and colleagues found an adjusted odds ratio of 1.88 for complete reporting of at least half the assessed CONSORT items, with a 95% confidence interval of 1.03 to 3.42, indicating a modest association whose lower bound lies just above one.
  • “A congress abstract is not a publication, so no disclosure is required.” It constitutes prior public presentation of the data. It should be disclosed in the cover letter and cited; disclosure has no cost, whereas non-disclosure can lead to retraction.
  • “GPP is a set of rules imposed by a committee.” GPP3 was developed from 241 applications and an 18-member steering committee drawn from 7 countries, with 94 of 174 selected reviewers commenting on the second draft. It is a consensus document, and understanding its development clarifies how its recommendations may be interpreted and contested.

Uses and limitations of worked examples

Examples are useful because they demonstrate the wording, and wording is where compliance most often succeeds or fails. They are hazardous for the same reason: wording that fits one set of facts may be copied into a manuscript with different facts, producing a statement that is precise but untrue.

The cases that follow should therefore be read as demonstrations of the reasoning, and the text should be adapted to match what actually occurred. Each case presents the situation, the instrument that governs it, what the instrument requires, and the text that satisfies it. The underlying requirements are set out systematically in the GPP reporting standards reference, and a single publication is followed from start to finish in the worked application page.

Case one: honorary authorship

The situation. A phase III manuscript is nearly final. The author list includes the head of department at the lead site, who secured the site’s participation, chaired two investigator meetings, read the penultimate draft and sent a one-line approval. He has not contributed to design, analysis or interpretation, has not revised the text, and does not intend to do so.

What governs it. The ICMJE authorship criteria, which GPP adopts rather than replaces. All four must be met: substantial contribution to conception or design, or to acquisition, analysis or interpretation; drafting or critical revision; approval of the final version; and accountability for the integrity of the work 1,5. He meets the third criterion. He does not meet the first two in any form that withstands explicit description.

What to do. The contributorship statement should be written before the author list is reopened. Describing what each person did makes the problem evident and depersonalises the discussion: the question becomes “what sentence do we write about him?” rather than “should we remove him?”. Securing a site’s participation and chairing investigator meetings are substantial contributions that merit acknowledgement, and the acknowledgement can state exactly that. Davidoff and colleagues made the structural case in Annals of Internal Medicine: a named author who is not in a position to answer for the work presents a problem for the reader, regardless of what the author line asserts 30. Rennie, Flanagin and Yank made the same argument in JAMA when they proposed describing contributions instead 31.

The wording. “We thank Professor R.S. (Department of Cardiology, Lead Hospital) for securing institutional participation and for chairing the investigator meetings. Professor R.S. did not contribute to the design, analysis or drafting of this report and does not meet ICMJE authorship criteria; he has consented to this acknowledgement.” The criteria are set out in full in using the ICMJE Recommendations.

Case two: a first draft written by a professional medical writer

The situation. A medical communications agency, paid by the sponsor, produced the first full draft from the clinical study report and an outline agreed with the lead author. The named authors revised it substantially over three rounds. No decision has been made about how to describe the writer’s contribution.

What governs it. GPP, together with the position statements of the professional bodies: Hamilton and Royer for AMWA, Jacobs and Wager for EMWA in Current Medical Research and Opinion, and Norris and colleagues for ISMPP. All three express the same position: writing support is a legitimate service, it does not constitute authorship unless the ICMJE criteria are met, and the remedy for ghostwriting is to name the writer rather than to forgo writing support 21,24,27. Gotzsche and colleagues set out in PLoS Medicine the measures the field had concluded were necessary, in response to the practice that Ross and colleagues documented in JAMA from the rofecoxib litigation and Hill and colleagues documented in Annals of Internal Medicine in the ADVANTAGE trial 16,17,20.

What the evidence says about it. Precision is more appropriate here than reassurance. Gattrell and colleagues, in BMJ Open, examined 233 randomised controlled trial reports 7. Of those with declared professional medical writing support, 39.1% (43 of 110) completely reported at least half of the assessed Consolidated Standards of Reporting Trials (CONSORT) items, compared with 21.1% (26 of 123) of those without support. After adjustment for publication year, the odds of completely reporting at least 50% of CONSORT items were 1.88 times higher with writing support (95% confidence interval 1.03 to 3.42) 7. This is a genuine association with a lower bound only just above one, in a cross-sectional design that cannot separate the contribution of the writer from the other features of a well-resourced publication process 6,7. It is a reason to declare support honestly; it is not evidence that engaging a writer improves reporting.

What to do. The disclosure should name the person, their employer, the funder, the work performed, and the fact that the person does not meet authorship criteria, and the person’s consent to be named should be obtained. Two versions of this statement are presented later in this article.

39.1%with declared writing support reported at least half the CONSORT items completely (43/110)
21.1%without writing support did so (26/123)
OR 1.88adjusted odds of completely reporting at least 50% of items
1.03–3.4295% confidence interval — the lower bound sits just above one

Cross-sectional analysis of 233 randomised controlled trial reports; the odds ratio is adjusted for publication year. The design cannot separate the writer’s contribution from other features of a well-resourced publication process. Source: Gattrell WT, Hopewell S, Young K, Farrow P, White R, Wager E, Winchester CC. Professional medical writing support and the quality of randomised controlled trial reporting: a cross-sectional study. BMJ Open.

Case three: an unfavourable result with no publication plan

The situation. A completed trial missed its primary endpoint. Eighteen months later, the clinical study report exists, no manuscript has been started, and the publication plan has been revised twice without including the study. No one has decided not to publish; the study is simply never scheduled.

What governs it. This is one of the four areas that GPP3 added as new sections: alongside principles for company-sponsored medical research, data sharing and plagiarism, it introduced explicit guidance on which studies should be published 8. The obligation to publish regardless of the direction of the result dates from the first GPP edition by Wager, Field and Grossman, but GPP3 made it a section rather than a sentence, because a single sentence had proved easy to leave unimplemented 28,29.

Why the guideline treats it as serious. Angell, in JAMA, described the structural incentives that produce precisely this outcome, and the review by Hill and colleagues of the ADVANTAGE internal documents showed how publication decisions made for commercial reasons appear from the inside 18,20. Non-publication of an unfavourable trial is not a neutral omission: it removes evidence that clinicians and systematic reviewers would otherwise weigh, and the participants consented on the understanding that the results would be used.

What to do. The study should be placed on the plan with a named owner and a dated milestone, and the decision should be recorded in writing. Where the finding is genuinely uninterpretable, as in a trial stopped early because of recruitment failure, it can still be published as a brief report stating what was done and why the trial stopped. GPP distinguishes between a study that cannot support a conclusion and a study whose conclusion is unwelcome. The former may be reported briefly; the latter must be reported in full.

Case four: data previously presented at a congress

The situation. Interim results were presented as a late-breaking abstract, and the abstract was published in a congress supplement. The full paper reports the same primary endpoint with longer follow-up. A press release was issued at the time of the congress. The authors are uncertain what should be disclosed.

What governs it. The ICMJE provisions on overlapping publication. A congress abstract is generally accepted as prior presentation rather than prior publication, but it is nonetheless a public appearance of the data, and the editor decides; the editor must therefore be informed 1. Von Elm and colleagues, in JAMA, showed the consequences of undisclosed overlap: in their analysis of articles used in systematic reviews, the harmful duplicates were those carrying no cross-reference to the main article 25. DeAngelis presented the editorial view in JAMA, and Alfonso, Bermejo and Segovia set out the costs in Revista Espanola de Cardiologia 23,26.

What to do. Three steps are required, none of them time-consuming. The abstract and the congress should be disclosed in the cover letter, by citation. The abstract should be cited in the manuscript at the point where the overlapping results appear. The manuscript should state explicitly what is new in the full paper, in this case longer follow-up and the complete safety dataset. Regarding the press release, Woloshin and colleagues showed in Annals of Internal Medicine that press releases frequently overstate what the underlying work supports; authors should therefore verify that the release claims no more than the manuscript does. Any such discrepancy is part of the public record, and a reviewer may identify it 14.

The boundary between acceptable secondary reporting and duplicate publication is discussed in detail in duplicate publication, and the means by which an editor would detect overlap in identification of multiple publication.

Case five: an external request for individual participant data

The situation. Eight months after publication, an academic group preparing a meta-analysis requests the individual participant data. The paper’s data availability statement says that the data are available on reasonable request from the corresponding author. The corresponding author has since moved institutions, and the sponsor holds the database.

What governs it. Data sharing is the second of the four areas that GPP3 added as new sections, and the ICMJE requires a data sharing statement in manuscripts reporting clinical trial results 1,8. The problem in this case is not the request but that the statement committed to a mechanism that was never established.

What to do now. The request should be answered on the basis of what actually exists (who holds the data, what the consent permits, what review the sponsor requires, and what agreement the requester must sign), and the response should be prompt even if it is partly negative. A slow non-response to a documented request is the least acceptable outcome, because the statement is part of the published record.

What to do next time. The statement should describe a mechanism rather than a willingness: which data and documents, to whom, decided by whom, from when, for how long, by what route, under what agreement, and on what consent basis. If the consent does not support sharing, the statement should say so and give the reason; this satisfies the requirement, and an honest refusal is defensible where an unfulfilled promise is not. The current position, including data protection constraints, is discussed in recent trends in GPP.

The five cases, the instrument, and the deliverable

SituationWhat governs itWhat you actually produce
A name on the list that does not meet the criteriaICMJE authorship criteria, adopted by GPPA contributorship statement written before the list is reopened, plus an acknowledgement naming the real contribution and stating that the criteria are not met
A professional drafted the paperGPP; AMWA, EMWA and ISMPP position statementsA disclosure naming person, employer, funder, scope, non-authorship and consent to be named
An unfavourable result that no one is schedulingGPP3 section on studies that should be published; the publish-regardless principle from GPP 2003The study on the publication plan with a named owner and a dated milestone, and the decision recorded in writing
Data already presented at a congressICMJE provisions on overlapping publicationCover-letter disclosure by citation, a citation to the abstract at the overlapping results, and a sentence stating what is new
An outside request for participant dataGPP3 section on data sharing; ICMJE data sharing statement requirementA statement specifying what, to whom, decided by whom, from when, for how long, by what route, under what agreement and on what consent basis

Instruments as cited in the reference list below. The deliverables represent Pubrica’s interpretation of what each requirement amounts to in a manuscript, not wording prescribed by any issuing body.

Development of the guideline as a worked example

A sixth example is instructive because it clarifies the nature of the document under discussion. GPP3, from Battisti and colleagues in Annals of Internal Medicine, was produced by a process that its authors described in some detail 8. ISMPP invited more than 3,000 publication professionals worldwide either to apply for the steering committee or to serve as reviewers 8. The GPP2 authors reviewed 241 applications and formed an 18-member steering committee drawn from 7 countries 8. Of 174 selected reviewers, 94 commented on the second draft, and the steering committee resolved those comments by discussion and consensus 8.

Two inferences follow. First, this is a consensus document rather than a derivation from principles, so where it is silent or ambiguous, the appropriate course is to examine practice and journal requirements rather than to reason from the text. Second, GPP3 added four new sections (principles for company-sponsored medical research, data sharing, studies that should be published, and plagiarism), and the inclusion of a topic as a new section is a reasonable indication that it was being handled poorly at the time. Three of the five cases above fall within these four additions, which is unlikely to be coincidental.

Two versions of the case two disclosure statement

This is the text with the greatest practical consequence, and the version on the left remains common. Both describe the same engagement: an agency writer produced the first draft from the clinical study report against an author-agreed outline, and the authors revised it over three rounds.

Disclosing writing support: the common version and the compliant one

Conceals more than it discloses

Acknowledgements: The authors would like to thank ABC Medical Communications for editorial support in the preparation of this manuscript, which was funded by XYZ Pharma. All authors reviewed and approved the final manuscript.

No person is named. An agency cannot be accountable for text; the wording leaves no individual answerable for what was written.

“Editorial support” does not distinguish copy-editing from drafting the paper. It is consistent with both, which is why it may be read as evasive.

Nothing rules out authorship-level contribution. A reader cannot tell whether the writer made interpretive decisions, which is the question that determines whether she should be an author.

“All authors reviewed and approved” asserts compliance rather than describing contributions, so the ICMJE criteria cannot be checked.

No record of consent. Naming a person in an acknowledgement requires their agreement; omitting the name avoids the question by omitting the person.

Satisfies GPP and the professional statements

Acknowledgements: Medical writing support was provided by Jane Smith, PhD, of ABC Medical Communications, Reading, UK, and was funded by XYZ Pharma. Dr Smith prepared the first draft from the clinical study report against an outline agreed by all authors, incorporated the authors’ revisions across three rounds, and conducted reference verification; she did not contribute to the design, conduct, analysis or interpretation of the study, does not meet ICMJE authorship criteria, and has consented to being named here. Contributorship: A.B. and C.D. designed the study; C.D. and E.F. acquired the data; G.H., a statistician employed by XYZ Pharma, conducted the pre-specified analyses; A.B., E.F. and G.H. interpreted the results; all authors critically revised the manuscript, approved the version submitted, and agree to be accountable for the integrity of the work.

The writer is named, with qualification, employer, location and funder.

Her scope is itemised — first draft, revisions, reference verification — and the exclusions are explicit, so the non-authorship conclusion is checkable rather than asserted.

Her consent to be named is recorded, which is a requirement in its own right.

Each author’s contribution is described, including the sponsor-employed statistician, so all four ICMJE criteria can be verified against the statement.

Nothing is claimed that the facts do not support, which allows the statement to withstand sceptical review.

The second version is approximately eighty words longer and contains no new facts, only facts that were already known internally. This reflects the general nature of GPP compliance: the work lies in recording what was done, not in changing it. It also explains why retrospective compliance is difficult: if the writer’s scope was never agreed in advance, this statement cannot be written honestly at submission.

Limitations of these examples

Three limitations should be stated. First, every wording above assumes that the underlying facts are as described; if the writer in case two also made analytical decisions, she may meet the authorship criteria, and the correct answer changes. The examples illustrate the test, not the answer.

Second, the evidence base for the recommendations is uneven. The positions on authorship and overlap rest on documented harm: von Elm and colleagues on duplication, and Ross and Hill on authorship practice 17,20,25. The writing-support recommendation rests on the association reported by Gattrell and colleagues, with a confidence interval of 1.03 to 3.42, which is weak evidence, and on professional consensus, which is not evidence 7. Declaring writing support is clearly appropriate; the data do not, however, show that it improves papers.

Third, there is no published measure of how often these practices are followed. Titus, Wells and Rhoades argued in Nature that research integrity requires institutional repair rather than additional codes, and nothing in the GPP literature addresses that argument for publication practice specifically 19. Where a case does not resemble any of the five above, the reliable approach is to record what actually happened, review it, and consider whether a reader would feel misled. This test addresses most of the purposes of the guideline. If the answer is unclear, the journal should be consulted; Pubrica’s publication ethics hub sets out which instrument governs which question.

Key points

Key points

GPP is most useful when applied to specific situations. An author who fails any of the four ICMJE criteria should be listed in the acknowledgements with their actual contribution described. A professional writer should be disclosed by person, employer, funder and scope, with their consent; the evidence that such disclosure improves papers is weaker than is often assumed, with Gattrell and colleagues reporting an adjusted odds ratio of 1.88 and a confidence interval of 1.03 to 3.42. An unfavourable result should be placed on the publication plan with an owner and a date. Data previously presented at a congress should be disclosed in the cover letter and cited in the paper. A data sharing statement should describe a mechanism or explicitly decline to share. Three of these five situations fall within the four sections added in GPP3, which indicates where practice was weakest.

Application to your study

Application to your study

  1. The contributorship statement should be written before the author list is finalised. Describing contributions converts a political discussion into an editorial one and resolves most authorship disputes.
  2. The writer’s scope should be agreed in writing before drafting begins. Without prior agreement, an accurate disclosure cannot be written at submission; this is the one item that cannot be established retrospectively.
  3. Written consent should be obtained from every person named in the acknowledgements, including the writer, and retained with the submission file.
  4. The publication plan should be checked for completed studies with no milestone. Any trial with a clinical study report but no owner and no date represents the case three problem, irrespective of the plan’s stated intent.
  5. Every prior public presentation of the data should be listed before the cover letter is written (congress abstracts, posters, late-breaking presentations, press releases and registry postings) and disclosed by citation.
  6. Press releases should be checked against the manuscript’s conclusion. Any claim in the release that the paper does not support is a discrepancy already in the public record.
  7. The phrase “available on reasonable request” should be replaced with a specified mechanism that a person other than the corresponding author could operate in five years’ time.
  8. Where no example applies, authors should record what actually occurred and review it critically. If a reader would feel misled by the published version, that version is inadequate, irrespective of the literal wording of the guideline.

Frequently asked questions

The name should be tested against all four ICMJE authorship criteria and the result recorded. A person who secured a site’s participation and approved the final draft meets the approval criterion but not the contribution or revision criteria, and all four must be met. The practical approach is to draft the contributorship statement before reopening the author list: once each person’s role is described in a sentence, the problem is apparent to all, and the discussion concerns wording rather than status. The actual contribution should be acknowledged explicitly (securing participation and chairing investigator meetings are substantial and merit naming), the acknowledgement should state that ICMJE criteria are not met, and consent for the acknowledgement should be obtained.

The disclosure should name the individual, their qualification, their employer and location, and the funder; describe what the individual did and did not do; state that the individual does not meet ICMJE authorship criteria; and record that the individual has consented to be named. The inadequate version is “the authors thank ABC Medical Communications for editorial support, funded by XYZ Pharma”: it names no person, so no one is accountable; it specifies no scope, so copy-editing and drafting the entire paper are indistinguishable; and it provides nothing that allows a reader to judge whether the writer should in fact have been an author. The professional bodies (AMWA, EMWA and ISMPP) all take the position that declared support is legitimate and that concealment is the problem.

The association is genuine but modest, and the design cannot establish causation. Gattrell and colleagues, in BMJ Open, examined 233 randomised controlled trial reports: 39.1% (43 of 110) of those with declared professional writing support completely reported at least half of the assessed CONSORT items, compared with 21.1% (26 of 123) of those without. After adjustment for publication year, the odds of completely reporting at least 50% of items were 1.88 times higher with support (95% confidence interval 1.03 to 3.42). The lower bound lies just above one, and a cross-sectional comparison cannot separate the writer from the other features of a well-resourced publication process. Support should be declared because concealment is wrong, not because the data indicate a better paper.

That it be published nonetheless. The principle dates from the first GPP edition, by Wager, Field and Grossman, and GPP3 made it a section of its own, one of four new sections it added alongside principles for company-sponsored medical research, data sharing and plagiarism. In practice, the failure is passive rather than deliberate: no one decides against publication; the study is simply never scheduled. The remedy is procedural: the study should be placed on the publication plan with a named owner and a dated milestone, and the decision recorded. Where a study genuinely cannot support a conclusion, for example because it was stopped early for recruitment failure, a brief report stating what was done and why it stopped is an acceptable form of publication.

Normally not, but the editor decides and must therefore be informed. A congress abstract is generally treated as prior presentation rather than prior publication under the ICMJE provisions on overlapping publication. Three steps ensure appropriate handling: disclosing the abstract and congress by citation in the cover letter; citing the abstract in the manuscript where the overlapping results appear; and stating what the full paper adds, such as longer follow-up or the complete safety dataset. Von Elm and colleagues, in JAMA, found that the duplicates causing real harm in systematic reviews were those carrying no cross-reference to the main article; concealment, rather than overlap, is what causes the damage.

The request should be answered promptly on the basis of what actually exists, even if the answer is partly negative. The authors should establish who holds the database, what the consent permits, what review the sponsor requires and what agreement the requester would have to sign, and then reply accordingly. A slow non-response is the least acceptable outcome, because the commitment is part of the published record. For future papers, the statement should describe a mechanism rather than a willingness: which data and documents, to whom, decided by whom, from when, for how long, by what route, under what agreement, and on what consent basis. Where consent does not support sharing, the statement should say so and give the reason; an honest refusal is defensible, whereas an unfulfilled promise is not.

ISMPP invited more than 3,000 publication professionals worldwide to apply for the steering committee or to serve as reviewers. The GPP2 authors reviewed 241 applications and formed an 18-member steering committee from 7 countries. Of 174 selected reviewers, 94 commented on the second draft, and the steering committee resolved those comments by discussion and consensus. This matters because it indicates the nature of GPP: a negotiated consensus rather than a derivation from first principles. Where it is silent or ambiguous, closer reasoning from the text will not yield an answer; examination of current journal requirements and prevailing practice will.

Authors should record what actually happened, in plain sentences, as if for inclusion in the paper, and then consider whether a reader seeing only the published version would feel misled. This test addresses most of what these guidelines exist to prevent, because almost every failure in this area is a discrepancy between what happened and what the record states. If the answer is genuinely unclear (for example, recycled methods text, a preprint already posted, or a secondary publication in another language), the journal should be consulted in writing before submission. The editor’s answer is decisive; the authors’ interpretation of the guidance is not.

References

  1. International Committee of Medical Journal Editors. Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals. ICMJE. 2026. read 9 October 2026. icmje.org
  2. International Committee of Medical Journal Editors. The New ICMJE Recommendations (August 2013). ICMJE. 2013. read 9 October 2026. icmje.org
  3. Committee on Publication Ethics. Core Practices. COPE. read 9 October 2026. equator-network.org
  4. International Society for Medical Publication Professionals. GPP 2022: Good Publication Practice guidelines for company-sponsored biomedical research published in Annals of Internal Medicine (press release). ISMPP. 2022. read 9 October 2026. ismpp.org
  5. DeTora LM, Toroser D, Sykes A, Vanderlinden C, Plunkett FJ, Lane T, Hanekamp E, Dormer L, DiBiasi F, Bridges D, Baltzer L, Citrome L. Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update. Annals of Internal Medicine. 2022;175(9):1298-1304. doi:10.7326/M22-1460 read 9 October 2026. doi.org/10.7326/M22-1460
  6. Mills I, Sheard C, Hays M, Douglas K, Winchester CC, Gattrell WT. Professional medical writing support and the reporting quality of randomized controlled trial abstracts among high-impact general medical journals. F1000Research. 2017;6:1489. doi:10.12688/f1000research.12268.2 read 9 October 2026. doi.org/10.12688/f1000research.12268.2
  7. Gattrell WT, Hopewell S, Young K, Farrow P, White R, Wager E, Winchester CC. Professional medical writing support and the quality of randomised controlled trial reporting: a cross-sectional study. BMJ Open. 2016;6(2):e010329. doi:10.1136/bmjopen-2015-010329 read 9 October 2026. doi.org/10.1136/bmjopen-2015-010329
  8. Battisti WP, Wager E, Baltzer L, Bridges D, Cairns A, Carswell CI, Citrome L, Gurr JA, Mooney LA, Moore BJ, Pena T, Sanes-Miller CH, Veitch K, Woolley KL, Yarker YE. Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3. Annals of Internal Medicine. 2015;163(6):461-464. doi:10.7326/M15-0288 read 9 October 2026. doi.org/10.7326/M15-0288
  9. Wislar JS, Flanagin A, Fontanarosa PB, et al. Honorary and ghost authorship in high impact biomedical journals: a cross sectional survey. BMJ. 2011;343:d6128. doi:10.1136/bmj.d6128 read 9 October 2026. doi.org/10.1136/bmj.d6128
  10. Das N, Panjabi M. Plagiarism: why is it such a big issue for medical writers? Perspectives in Clinical Research. 2011;2(2):67-71. doi:10.4103/2229-3485.80370 read 9 October 2026. doi.org/10.4103/2229-3485.80370
  11. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Annals of Internal Medicine. 2010;152:726-732. read 9 October 2026. care-statement.org
  12. Graf C, Battisti WP, Bridges D, Bruce-Winkler V, Conaty JM, Ellison JM, Field EA, Gurr JA, Marx M-E, Patel M, Sanes-Miller C, Yarker YE. Good publication practice for communicating company sponsored medical research: the GPP2 guidelines. BMJ. 2009;339:b4330. doi:10.1136/bmj.b4330 read 9 October 2026. doi.org/10.1136/bmj.b4330
  13. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine. 2009;6:e1000097. read 9 October 2026. care-statement.org
  14. Woloshin S, Schwartz LM, Casella SL, Kennedy AT, Larson RJ. Press releases by academic medical centers: not so academic? Annals of Internal Medicine. 2009;150:613-618. read 9 October 2026. archive.emwa.org
  15. Rothman DJ, McDonald WJ, Berkowitz CD, Chimonas SC, DeAngelis CD, Hale RW, et al. Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest. JAMA. 2009;301(13):1367-1372. read 9 October 2026. equator-network.org
  16. Gotzsche PC, Kassirer JP, Woolley KL, Wager E, Jacobs A, Gertel A, et al. What should be done to tackle ghostwriting in the medical literature? PLoS Medicine. 2009;6(2):e1000023. read 9 October 2026. archive.emwa.org
  17. Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA. 2008;299:1800-1812. read 9 October 2026. archive.emwa.org
  18. Angell M. Industry-sponsored clinical research: a broken system. JAMA. 2008;300:1069-1071. read 9 October 2026. archive.emwa.org
  19. Titus SL, Wells JA, Rhoades LJ. Repairing research integrity. Nature. 2008;453:980-982. read 9 October 2026. archive.emwa.org
  20. Hill KP, Ross JS, Egilman DS, Krumholz HM. The ADVANTAGE seeding trial: a review of internal documents. Annals of Internal Medicine. 2008;149:251-258. read 9 October 2026. archive.emwa.org
  21. Norris R, Bowman A, Fagan JM, Gallagher ER, Geraci AB, Gertel A, et al. International Society for Medical Publication Professionals (ISMPP) position statement. Current Medical Research and Opinion. 2007;23:1837-1840. read 9 October 2026. archive.emwa.org
  22. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335:806-808. read 9 October 2026. care-statement.org
  23. Alfonso F, Bermejo J, Segovia J. Duplicate or redundant publication: can we afford it? Revista Espanola de Cardiologia. 2005;58(5):601-604. doi:10.1016/S1885-5857(06)60739-1 read 9 October 2026. doi.org/10.1016/S1885-5857(06)60739-1
  24. Jacobs A, Wager E. EMWA guidelines on the role of medical writers in developing peer-reviewed publications. Current Medical Research and Opinion. 2005;21:317-321. read 9 October 2026. archive.emwa.org
  25. von Elm E, Poglia G, Walder B, Tramer MR. Different patterns of duplicate publication: an analysis of articles used in systematic reviews. JAMA. 2004;291(8):974-980. doi:10.1001/jama.291.8.974 read 9 October 2026. doi.org/10.1001/jama.291.8.974
  26. DeAngelis CD. Duplicate publication, multiple problems. JAMA. 2004;292:1745-1746. doi:10.1001/jama.292.14.1745 read 9 October 2026. doi.org/10.1001/jama.292.14.1745
  27. Hamilton CW, Royer MG; AMWA 2002 Task Force on the Contributions of Medical Writers to Scientific Publications. AMWA position statement on the contributions of medical writers to scientific publications. AMWA Journal. 2003;18:13-16. read 9 October 2026. archive.emwa.org
  28. Wager E, Field EA, Grossman L. Good publication practice for pharmaceutical companies. Current Medical Research and Opinion. 2003;19(3):149-154. doi:10.1185/030079903125001767 read 9 October 2026. doi.org/10.1185/030079903125001767
  29. Wager E, Field EA, Grossman L. Good publication practice for pharmaceutical companies: why we need another set of guidelines. Current Medical Research and Opinion. 2003;19(3):147-148. read 9 October 2026. ismpp.org
  30. Davidoff F, DeAngelis CD, Drazen JM, Hoey J, Hojgaard L, Horton R, et al. Sponsorship, authorship, and accountability. Annals of Internal Medicine. 2001;135:463-466. read 9 October 2026. ismpp.org
  31. Rennie D, Flanagin A, Yank V. The contributions of authors. JAMA. 2000;284:89-91. read 9 October 2026. ismpp.org

Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.

How to cite this article

Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.

Pubrica Academy. (2026, October 9). Good Publication Practice Applied: Five Case Examples in Authorship, Disclosure and Data Sharing. Pubrica. https://pubrica.com/academy/concepts-definitions/example-of-gpp/

This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.

Case-by-case GPP decision record

One page per manuscript, completed before submission and retained with the submission file. It is a record rather than a checklist; its purpose is to ensure that the reasoning exists in writing should it be requested later.

GPP DECISION RECORD
Manuscript: ______________________   Study: ______________________
Target journal: ______________________   Completed by: ____________

A. AUTHORSHIP DECISIONS
   For every person considered for the author line, including those excluded:

   Name ______________________  Proposed role ______________________
     (1) Contributed to design / acquisition / analysis / interpretation?  Y / N
     (2) Drafted or critically revised?                                   Y / N
     (3) Approved the version to be submitted?                            Y / N
     (4) Agrees to be accountable for the work's integrity?               Y / N
     Decision: AUTHOR / ACKNOWLEDGED      Consent obtained? Y / N
     If acknowledged, the sentence describing the contribution:
     ______________________________________________________

   (Repeat for each person.)

B. WRITING SUPPORT
   Writer's name and qualification: ______________________
   Employer and location: ______________________
   Funder: ______________________
   Scope agreed in advance?  Y / N      Date agreed: ____________
   Scope as agreed: ______________________________________________
   Explicit exclusions (e.g. design, analysis, interpretation):
     ______________________________________________________
   Consent to be named obtained?  Y / N
   NOTE: if scope was not agreed before drafting, say so here rather than
   writing a disclosure the record does not support.

C. PRIOR PUBLIC APPEARANCE OF THESE DATA
   Congress abstract(s), with citation: ______________________
   Poster / oral presentation: ______________________
   Press release, with date: ______________________
   Preprint: ______________________
   Registry results posting: ______________________
   Earlier paper from the same cohort: ______________________
   [ ] All of the above disclosed in the cover letter by citation
   [ ] Overlapping results in the manuscript cite the earlier appearance
   [ ] The manuscript states what is new here
   [ ] Press release checked against the manuscript's conclusion

D. PUBLICATION OF THIS RESULT
   Direction of primary result: FAVOURABLE / UNFAVOURABLE / INCONCLUSIVE
   On the publication plan?  Y / N      Owner: ______________________
   Milestone date: ____________
   If not yet scheduled, reason recorded: ______________________

E. DATA SHARING STATEMENT
   WHAT data and documents: ______________________________________
   TO WHOM, and who decides: ______________________________________
   FROM WHEN / FOR HOW LONG: ______________________
   BY WHAT ROUTE: ______________________
   UNDER WHAT AGREEMENT: ______________________
   CONSENT BASIS, and what it does NOT permit: ____________________
   [ ] Read against the consent form by: ______________________

F. THE READ-BACK TEST
   Having read the disclosure, acknowledgement and contributorship text as a
   reader would, is there anything a reader would be misled about?
   ______________________________________________________
   Action taken: ______________________________________________

Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.

How Pubrica can help

Pubrica’s publication-support team routinely addresses these five situations: assessing an author list against the ICMJE criteria and drafting the contributorship text, preparing a writing-support disclosure that matches what was agreed, and revising data availability statements into mechanisms that remain operable in five years. Where a case is unresolved, Pubrica states this and assists in obtaining the editor’s position in writing before submission. Pubrica also indicates where the evidence behind a recommendation is weaker than its reputation suggests.

Find something else

Search the Pubrica Academy

Access is free and requires no account. Enter a topic, or open the full library to filter by category, sub-topic or resource type.

Advice on applying GPP to specific publication situations

A scoping assessment is free and takes two business days. It provides a written assessment of what the work requires and which specialist would undertake it.

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.